Zomiradomide is a PROTAC degradation agent targeting IRAK4, with oral bioavailability, and can also degrade Ikaros (IKZF1) and Aiolos (IKZF3), thereby inhibiting the NF-kappaB signalling pathway and activating the type I interferon signalling pathway, exhibiting anticancer activity against B-cell lymphoma.
Molecular Weight:
871.97
Purity:
98.41%
CAS Number:
[2655656-99-6]
Formula:
C45H48F3N7O6S
Target:
PROTACs|||NF-kappaB|||IRAK|||IKZF|||IFNAR
T75136
* VAT and and shipping costs not included. Errors and price changes excepted
